Rein Therapeutics, Inc.

Rein Therapeutics is a biopharmaceutical company developing therapeutic candidates for orphan pulmonary and fibrosis indications. The company's lead program, LTI-03, is a peptide currently in Phase 1b clinical trials for idiopathic pulmonary fibrosis (IPF). The company also developed LTI-01, a proenzyme that has advanced through Phase 1b and Phase 2a clinical trials for loculated pleural effusion. Additional pipeline candidates include LTI-05, an epithelial sodium channel inhibitor targeting cystic fibrosis, alongside preclinical programs in cystic fibrosis and a caveolin-1-focused peptide program for systemic fibrosis indications.

The company operates with a small team of 11 full-time employees and is headquartered in Austin, Texas. As a clinical-stage biopharmaceutical company with no disclosed revenue streams, Rein Therapeutics remains in development phase with all candidates in early clinical or preclinical stages. The company was originally incorporated in 2001 as Aileron Therapeutics before rebranding to Rein Therapeutics in 2007, and is traded on the Nasdaq exchange.